Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1998 2
1999 2
2000 3
2001 1
2002 3
2003 4
2004 3
2005 3
2006 6
2007 5
2008 7
2009 5
2010 4
2011 6
2012 4
2013 6
2014 7
2015 11
2016 10
2017 6
2018 6
2019 7
2020 8
2021 7
2022 10
2023 4
2024 1
2025 2
2026 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

129 results

Results by year

Filters applied: . Clear all
Page 1
Insight into mode-of-action and structural determinants of the compstatin family of clinical complement inhibitors.
Lamers C, Xue X, Smieško M, van Son H, Wagner B, Berger N, Sfyroera G, Gros P, Lambris JD, Ricklin D. Lamers C, et al. Nat Commun. 2022 Sep 20;13(1):5519. doi: 10.1038/s41467-022-33003-7. Nat Commun. 2022. PMID: 36127336 Free PMC article.
Moreover, compstatin derivatives with enhanced pharmacodynamic and pharmacokinetic profiles are in clinical development (e.g., Cp40/AMY-101). ...Our study may thereby guide the application of existing and development of next-generation compstatin analogs....
Moreover, compstatin derivatives with enhanced pharmacodynamic and pharmacokinetic profiles are in clinical development (e.g., Cp40/A …
Application of the C3 inhibitor compstatin in a human whole blood model designed for complement research - 20 years of experience and future perspectives.
Mollnes TE, Storm BS, Brekke OL, Nilsson PH, Lambris JD. Mollnes TE, et al. Semin Immunol. 2022 Jan;59:101604. doi: 10.1016/j.smim.2022.101604. Epub 2022 May 13. Semin Immunol. 2022. PMID: 35570131 Free article. Review.
For instance, to examine the relative roles of C3 and C5 in complement activation, it is possible to compare the effects of the C3 inhibitor compstatin effects to those of inhibitors of C5 and C5aR1. We also discuss how complement is activated by both pathogen-associated m …
For instance, to examine the relative roles of C3 and C5 in complement activation, it is possible to compare the effects of the C3 inhibitor …
Compstatin: a C3-targeted complement inhibitor reaching its prime for bedside intervention.
Mastellos DC, Yancopoulou D, Kokkinos P, Huber-Lang M, Hajishengallis G, Biglarnia AR, Lupu F, Nilsson B, Risitano AM, Ricklin D, Lambris JD. Mastellos DC, et al. Eur J Clin Invest. 2015 Apr;45(4):423-40. doi: 10.1111/eci.12419. Epub 2015 Mar 9. Eur J Clin Invest. 2015. PMID: 25678219 Free PMC article. Review.
Indeed, the introduction of the first complement-targeting drugs has reignited a vibrant interest in the clinical translation of complement-based inhibitors. Compstatin was discovered as a cyclic peptide that inhibits complement activation by binding C3 and interfering wit …
Indeed, the introduction of the first complement-targeting drugs has reignited a vibrant interest in the clinical translation of complement- …
Innate immune responses to trauma.
Huber-Lang M, Lambris JD, Ward PA. Huber-Lang M, et al. Nat Immunol. 2018 Apr;19(4):327-341. doi: 10.1038/s41590-018-0064-8. Epub 2018 Mar 5. Nat Immunol. 2018. PMID: 29507356 Free PMC article. Review.
Considering innate immune responses in SARS-CoV-2 infection and COVID-19.
Diamond MS, Lambris JD, Ting JP, Tsang JS. Diamond MS, et al. Nat Rev Immunol. 2022 Aug;22(8):465-470. doi: 10.1038/s41577-022-00744-x. Epub 2022 Jul 4. Nat Rev Immunol. 2022. PMID: 35788185 Free PMC article.
In early 2022, Program staff from the NIAID at the NIH organized a workshop focusing on the innate immune response to SARS-CoV-2 infection and during COVID-19, which was chaired by Ralph Baric, Jenny Ting and John Lambris. Following the meeting, Nature Reviews Immunology i …
In early 2022, Program staff from the NIAID at the NIH organized a workshop focusing on the innate immune response to SARS-CoV-2 infection a …
Clinical promise of next-generation complement therapeutics.
Mastellos DC, Ricklin D, Lambris JD. Mastellos DC, et al. Nat Rev Drug Discov. 2019 Sep;18(9):707-729. doi: 10.1038/s41573-019-0031-6. Epub 2019 Jul 19. Nat Rev Drug Discov. 2019. PMID: 31324874 Free PMC article. Review.
Compstatin: a complement inhibitor on its way to clinical application.
Ricklin D, Lambris JD. Ricklin D, et al. Adv Exp Med Biol. 2008;632:273-92. doi: 10.1007/978-0-387-78952-1_20. Adv Exp Med Biol. 2008. PMID: 19025129 Free PMC article. Review.
With the recent announcement of clinical trials with a compstatin analog for the treatment of age-related macular degeneration, another important milestone has been reached on its way to a drug. ...Considering the new incentives and the promising pre-clinical results, c …
With the recent announcement of clinical trials with a compstatin analog for the treatment of age-related macular degeneration, anoth …
Thermodynamic studies on the interaction of the third complement component and its inhibitor, compstatin.
Katragadda M, Morikis D, Lambris JD. Katragadda M, et al. J Biol Chem. 2004 Dec 31;279(53):54987-95. doi: 10.1074/jbc.M409963200. Epub 2004 Oct 15. J Biol Chem. 2004. PMID: 15489226 Free article.
Compstatin is a 13-residue cyclic peptide that inhibits complement activation by binding to complement component, C3. ...In the present study, isothermal titration calorimetry was employed to dissect the molecular forces that govern the interaction of compstatin wit …
Compstatin is a 13-residue cyclic peptide that inhibits complement activation by binding to complement component, C3. ...In the prese …
Binding kinetics, structure-activity relationship, and biotransformation of the complement inhibitor compstatin.
Sahu A, Soulika AM, Morikis D, Spruce L, Moore WT, Lambris JD. Sahu A, et al. J Immunol. 2000 Sep 1;165(5):2491-9. doi: 10.4049/jimmunol.165.5.2491. J Immunol. 2000. PMID: 10946275
We have previously identified a 13-residue cyclic peptide, Compstatin, that binds to complement component C3 and inhibits complement activation. Herein, we describe the binding kinetics, structure-activity relationship, and biotransformation of Compstatin. Biomolecu …
We have previously identified a 13-residue cyclic peptide, Compstatin, that binds to complement component C3 and inhibits complement …
Compstatin inhibits complement and cellular activation in whole blood in two models of extracorporeal circulation.
Nilsson B, Larsson R, Hong J, Elgue G, Ekdahl KN, Sahu A, Lambris JD. Nilsson B, et al. Blood. 1998 Sep 1;92(5):1661-7. Blood. 1998. PMID: 9716594 Free article.
Compstatin effectively inhibited the generation of C3a and sC5b-9 and the binding of C3/ C3 fragments to the polymer surface. ...These data show that complement activation, leading to activation and binding of PMNs to the biomaterial surface, can be abolished by the additi …
Compstatin effectively inhibited the generation of C3a and sC5b-9 and the binding of C3/ C3 fragments to the polymer surface. ...Thes …
129 results